BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 19016259)

  • 21. Lymph node metastases in diffuse malignant peritoneal mesothelioma.
    Baratti D; Kusamura S; Cabras AD; Laterza B; Balestra MR; Deraco M
    Ann Surg Oncol; 2010 Jan; 17(1):45-53. PubMed ID: 19856030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
    Ann Surg; 2007 Jan; 245(1):104-9. PubMed ID: 17197972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma.
    Laterza B; Kusamura S; Baratti D; Oliva GD; Deraco M
    In Vivo; 2009; 23(1):187-90. PubMed ID: 19368148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytoreductive surgery (cs) and hyperthermic intraperitoneal chemotherapy (hipec) in treatment of peritoneal surface malignances: report of a phase II clinical study.
    Asero S; Caruso M; Vallone N; Luciani AG; Lombardo V; Terranova G; Ettore G; Giannone G
    In Vivo; 2009; 23(4):645-7. PubMed ID: 19567402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive management of diffuse malignant peritoneal mesothelioma.
    Sugarbaker PH; Yan TD; Stuart OA; Yoo D
    Eur J Surg Oncol; 2006 Aug; 32(6):686-91. PubMed ID: 16621431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis.
    Hubert J; Thiboutot E; Dubé P; Cloutier AS; Drolet P; Sideris L
    Surg Oncol; 2015 Mar; 24(1):41-6. PubMed ID: 25680983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma.
    Deraco M; De Simone M; Rossi CR; Cavaliere F; Difilippo F; Scuderi S; Pilatti P; Kusamura S
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):41-5. PubMed ID: 16767905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology.
    Omohwo C; Nieroda CA; Studeman KD; Thieme H; Kostuik P; Ross AS; Holter DR; Gushchin V; Merriman B; Sardi A
    J Am Coll Surg; 2009 Sep; 209(3):308-12. PubMed ID: 19717034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity.
    Kusamura S; Baratti D; Younan R; Laterza B; Oliva GD; Costanzo P; Favaro M; Gavazzi C; Grosso F; Deraco M
    Ann Surg Oncol; 2007 Sep; 14(9):2550-8. PubMed ID: 17558537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
    Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
    Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant peritoneal mesothelioma.
    Bani-Hani KE; Gharaibeh KA
    J Surg Oncol; 2005 Jul; 91(1):17-25. PubMed ID: 15999348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ; van Ruth S; de Bree E; van Sloothen GW; van Tinteren H; Boot H; Zoetmulder FA
    J Clin Oncol; 2003 Oct; 21(20):3737-43. PubMed ID: 14551293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of treatment of 33 patients with peritoneal mesothelioma.
    Sebbag G; Yan H; Shmookler BM; Chang D; Sugarbaker PH
    Br J Surg; 2000 Nov; 87(11):1587-93. PubMed ID: 11091251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
    Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases.
    Chua TC; Quinn LE; Zhao J; Morris DL
    J Surg Oncol; 2013 Aug; 108(2):81-8. PubMed ID: 23737041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique.
    Kusamura S; Younan R; Baratti D; Costanzo P; Favaro M; Gavazzi C; Deraco M
    Cancer; 2006 Mar; 106(5):1144-53. PubMed ID: 16456817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program.
    Chua TC; Martin S; Saxena A; Liauw W; Yan TD; Zhao J; Lok I; Morris DL
    Ann Surg; 2010 Feb; 251(2):323-9. PubMed ID: 20040853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival.
    Gilani SNS; Mehta A; Garcia-Fadrique A; Rowaiye B; Jenei V; Dayal S; Chandrakumaran K; Carr N; Mohamed F; Cecil T; Moran B
    Int J Hyperthermia; 2018 Aug; 34(5):578-584. PubMed ID: 29431036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma.
    Yan TD; Yoo D; Sugarbaker PH
    Eur J Surg Oncol; 2006 Nov; 32(9):948-53. PubMed ID: 16806796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.